Clinical Trials Directory

Trials / Unknown

UnknownNCT03112733

Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers

Value of TFF3, SFRP4, Romo1 and NFKB as Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers

Status
Unknown
Phase
Study type
Observational
Enrollment
171 (actual)
Sponsor
Ilker Kahramanoglu · Academic / Other
Sex
Female
Age
18 Years – 70 Years
Healthy volunteers
Accepted

Summary

This study evaluates the usefulness of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB as potential diagnostic and prognostic biomarkers in ovarian carcinoma.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTTFF3, SFRP4, Romo1, NFKBBlood samples of all participants will be collected.

Timeline

Start date
2017-04-04
Primary completion
2018-06-21
Completion
2019-05-30
First posted
2017-04-13
Last updated
2019-02-26

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT03112733. Inclusion in this directory is not an endorsement.

Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers (NCT03112733) · Clinical Trials Directory